Primary prevention of coronary heart disease with drug therapy. Safety and total mortality issues
Grundy, S.M.
Archives of Internal Medicine 152(7): 1369-1371
1992
ISSN/ISBN: 0003-9926 PMID: 1627015 Document Number: 389256
Document emailed within 1 workday
Related Documents
Stamler, J. 1973: Heart disease prevention in industry. Primary prevention in mass community efforts to control the major coronary risk factors: the challenges and possibilities--critical issues and outlook for the future Journal of Occupational Medicine.: Official Publication of the Industrial Medical Association 15(1): 54-59Jenni, D.; Osterwalder, R.; Osswald, S.; Buser, P.; Pfisterer, M. 2001: Are we treating coronary heart disease and heart failure appropriately in the clinic and ambulatory care? Secondary prevention and drug therapy 1998 Praxis 90(41): 1759-1765
Martens, L.L.; Guibert, R. 1994: Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease Clinical Therapeutics 16(6): 1052-62; discussion 1036
Kannel, W.B. 1990: Implications of the primary prevention trials against coronary heart disease Journal of Hypertension. Supplement: Official Journal of the International Society of Hypertension 8(7): S245-S250
Meinertz, T.; Heitzer, T. 2002: Primary and secondary prevention of coronary heart disease: smoking Zeitschrift für Kardiologie 91 Suppl. 2: 3-11
Gliksman, M.D.; Dwyer, T.; Boulton, T.J. 1987: Should the primary prevention of coronary heart disease commence in childhood? Medical Journal of Australia 146(7): 360-362
Wicklmayr, M.; Rett, K.; Standl, E. 1994: How can primary prevention of coronary heart disease be improved in general practice? Medizinische Klinik 89(4): 184-6 229
Carneiro, Aónio.Vaz.; Costa, Jão.; Borges, M. 2004: Statins for primary and secondary prevention of coronary heart disease. A scientific review Revista Portuguesa de Cardiologia: Orgao Oficial da Sociedade Portuguesa de Cardiologia 23(1): 95-122
Wilhelmsen, L. 1977: Primary and secondary risk factors for coronary heart disease: their role in prevention Medical Journal of Malaysia 31(4): 296-301
Goldbourt, U.; Yaari, S.; Medalie, J.H. 1993: Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees. A 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study Cardiology 82(2-3): 100-121
Kocemba, J.; Kawecka-Jaszcz, K.; Magdoń, M. 1981: The effect of six years lasting primary non pharmacological prevention of coronary heart disease on hypercholesterolemia in occupationally working men Przeglad Lekarski 38(12): 857-860
Böhm, C.; Christl, H.L.; Wald, G. 1982: Drug therapy of coronary heart disease. Comparative effects of nifedipine and isosorbide dinitrate Die Medizinische Welt 33(36): 1242-1244
Kłosiewicz-Latoszek, L.; Respondek, W.; Białobrzeska-Paluszkiewicz, J.; Grzybowska, B.; Jakóbisiak-Ostasz, B.; Stolarska, I. 2003: Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 15(85): 42-46
1980: W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators Lancet 2(8191): 379-385
Eng, P.M.; Rimm, E.B.; Fitzmaurice, G.; Kawachi, I. 2001: Social ties and change in social ties in relation to subsequent total and cause-specific mortality and coronary heart disease American Journal of Epidemiology 153(11 Suppl): S98
Savonitto, S.; Ambrosini, V.; Marzocchi, A.; Tolaro, S.; Petronio, A.S.; Galassi, A.R.; Bongo, A.S.; Gaglione, A.; Bolognese, L. 2005: Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 6(2): 106-118
Pignone, M.; Mulrow, C. 2002: Antiplatelet therapy and atherosclerotic events. Risks and patients' values need to be included in decision about aspirin for prevention of coronary heart disease Bmj 324(7342): 917
Kittel, F.; Kornitzer, M.; De Backer, G.; Dramaix, M. 1982: The Belgian Heart Disease Prevention Project: type A behavior pattern and the prevalence of coronary heart disease Activitas Nervosa Superior Suppl. 3(Pt 1): 78-83
Prichard, B.N. 1990: Pharmacological and clinical aspects of drug therapy in coronary heart disease: clinical aspects of therapy with beta-adrenoceptor antagonists Zeitschrift für Kardiologie 79(Suppl 3): 99-103
Umbrasiene, E.; Ventsloviene, Ĭ.; Babarskiene, R.M. 2011: Resting heart rate and one year mortality association in patients with coronary heart disease Kardiologiia 51(10): 15-20